TY - JOUR
AU - Hoang, Karen
AU - Watt, Hilary
AU - Golemme, Mara
AU - Perry, Richard J.
AU - Ritchie, Craig
AU - Wilson, Danielle
AU - Pickett, James
AU - Fox, Chris
AU - Howard, Robert
AU - Malhotra, Paresh A
PY - 2022
DA - August
TI - Noradrenergic Add-on Therapy with Extended-Release Guanfacine in Alzheimer's Disease (NorAD): study protocol for a randomised clinical trial and COVID-19 amendments
JO - Trials
VL - 23
IS - 1
DO - https://doi.org/10.1186/s13063-022-06190-3
AB - BACKGROUND: Guanfacine is a α2A adrenergic receptor agonist approved for treating attention deficit hyperactivity disorder (ADHD). It is thought to act via postsynaptic receptors in the prefrontal cortex, modulating executive functions including the regulation of attention. Attention is affected early in Alzheimer's disease (AD), and this may relate to pathological changes within the locus coeruleus, the main source of noradrenergic pathways within the brain. Given that cholinergic pathways, also involved in attention, are disrupted in AD, the combination of noradrenergic and cholinergic treatments may have a synergistic effect on symptomatic AD. The primary objective of the NorAD trial is to evaluate the change in cognition with 12 weeks of treatment of extended-release guanfacine (GXR) against a placebo as a combination therapy with cholinesterase inhibitors in participants with mild to moderate Alzheimer's disease.
PB - Springer Nature
UR - https://www.research.ed.ac.uk/en/publications/cb394c26-3b79-4296-9fc7-e375da06a144
KW - Coronavirus (COVID-19)
KW - Older people
ER